G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates. Source
No articles found.
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Meridian is a fully integrated life science company that develops, manufactures, m...
Meridian is a fully integrated life science com...
Arvinas is a biopharmaceutical company dedicated to improving the lives of patient...
Arvinas is a biopharmaceutical company dedicate...
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused ...
DiaMedica Therapeutics Inc. is a clinical stage...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Join the National Investor Network and get the latest information with your interests in mind.